National Cancer Institute; Notice of Meeting

Download PDF
Federal RegisterMar 2, 2021
86 Fed. Reg. 12196 (Mar. 2, 2021)

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website ( http://videocast.nih.gov ).

Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC), Ad hoc Translational Research Strategy Subcommittee.

Date: March 29, 2021.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: Group Discussion of Opportunities and Gaps in Translational Research.

Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting).

Contact Person: Peter Ujhazy, MD, Ph.D., Deputy Associate Director, Translational Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W106, Rockville, MD 20850, 240-276-5681, ujhazyp@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: https://deainfo.nci.nih.gov/advisory/ctac/subcommittees/index.htm,, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: February 24, 2021.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-04228 Filed 3-1-21; 8:45 am]

BILLING CODE 4140-01-P